Small molecule · developed by Mereo BioPharma
Leflutrozole (BGS649) is an oral capsule taken weekly for up to 24 weeks. It is studied in hypogonadotropic hypogonadism.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02908074 | Phase 2 | Hypogonadotropic Hypogonadism | Completed | MREO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hypogonadotropic Hypogonadism
Updated Oct 25, 2026. Something wrong or missing? Report it on the MREO page.
See MREO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MREO catalysts and pipeline →